

**Food and Drug Administration
Center for Drug Evaluation and Research
Oncologic Drugs Advisory Committee Meeting
September 13, 2005**

Meeting Participants

Consultants (voting), September 13, 2005

For Xinlay:

Otis Brawley, M.D.
Associate Director for Cancer Control
Professor of Medicine, Oncology and
Epidemiology
Winship Cancer Institute
Emory University School of Medicine
1365-B Clifton Road Suite B-4100
Atlanta, GA 30322

Ralph D'Agostino, Ph.D.
Professor of Mathematics/Statistics
Boston University
Mathematics Department
111 Cummington Street
Boston, MA 02215

S. Gail Eckhardt, M.D.
Cancer Center Program Director,
Developmental Therapeutics
University of Colorado Health Sciences
Center
Division of Oncology
12801 E. 17th Avenue
Aurora, CO 80010

Thomas Fleming, Ph.D.
University of Washington
School of Public Health and Community
Medicine
Department of Biostatistics
F600 Health Sciences Building
Seattle, WA 98195

Bruce Roth, M.D.
Professor of Medicine and Urologic Surgery
Vanderbilt-Ingram Cancer Center
777 Preston Research Building
Nashville, TN 37232-6301

For Tarceva:

Ralph D'Agostino, Ph.D.

S. Gail Eckhardt, M.D.

Patient Representatives (voting):

Eugene Kazmierczak, Ph.D. - For Xinlay
Jennifer

C. Wells – For Tarceva

**Center for Drug Evaluation and Research
Oncologic Drugs Advisory Committee Meeting
September 14, 2005**

Meeting Participants

Consultants (voting), September 14, 2005

For Revlimid:

S. Gail Eckhardt, M.D.
Cancer Center Program Director, Developmental Therapeutics
University of Colorado Health Sciences Center
Division of Oncology
12801 E. 17th Avenue
Aurora, CO 80010

Thomas Fleming, Ph.D.
University of Washington
School of Public Health and Community Medicine
Department of Biostatistics
F600 Health Sciences Building
Seattle WA 98195

Susan O' Brien, M.D.
Professor of Medicine
University of Texas, MD Anderson Cancer Center
Department of Leukemia
1515 Holcombe Blvd
Houston, TX 77030

For Nelarabine:

S. Gail Eckhardt, M.D.

Thomas Fleming, Ph.D.

Susan O' Brien, M.D.

Patient Representatives (voting):

Robert Carroll, Ph.D. – For Revlimid

Marilyn Eichner – For Nelarabine